Aequus Pharmaceuticals (AQSZF)

[BioSpecialist]

AQS1301 Topline Results within 10 days = Push to $0.40+
and there are many big news on the way to push this dirt cheap and unknown goldmine higher .This will be the next 10+ bagger after Theratechnologies (TH.T) and BioSyent (RX.V) . AQS is maybe the cheapest Bio gem you can get in the US.


Market-Cap: $15 Million
Cash: $4 Million << enough untill mid 2018
Price: $0.20


AQS1301 topline results in 1Q 2017

Operational profitability estimated in 2017

File for CDN approval of Topiramate XR in 1H 2017

File for CDN approval of Oxcarbazepine XR in 1H 2017

Additional Product acquisitions in 2017

Partnership for AQS1301 in 2017

Two products launches to date (Tacrolimus IR and Vistitan™)

3 long-acting, transdermal programs in development, on track to file NDA in 2018